- Home
- PIII vs PMN Comparison
PIII vs PMN Comparison
Compare PIII & PMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PIII
- PMN
- Stock Information
- Founded
- PIII 2015
- PMN 2004
- Country
- PIII United States
- PMN Canada
- Employees
- PIII N/A
- PMN N/A
- Industry
- PIII Medical/Nursing Services
- PMN Pharmaceuticals and Biotechnology
- Sector
- PIII Health Care
- PMN Health Care
- Exchange
- PIII Nasdaq
- PMN Nasdaq
- Market Cap
- PIII 32.2M
- PMN 33.7M
- IPO Year
- PIII N/A
- PMN N/A
- Fundamental
- Price
- PIII $0.19
- PMN $0.93
- Analyst Decision
- PIII Buy
- PMN
- Analyst Count
- PIII 3
- PMN 0
- Target Price
- PIII $2.38
- PMN N/A
- AVG Volume (30 Days)
- PIII 5.4M
- PMN 49.6K
- Earning Date
- PIII 11-12-2024
- PMN 11-14-2024
- Dividend Yield
- PIII N/A
- PMN N/A
- EPS Growth
- PIII N/A
- PMN N/A
- EPS
- PIII N/A
- PMN N/A
- Revenue
- PIII $1,476,630,000.00
- PMN N/A
- Revenue This Year
- PIII $21.45
- PMN N/A
- Revenue Next Year
- PIII N/A
- PMN N/A
- P/E Ratio
- PIII N/A
- PMN N/A
- Revenue Growth
- PIII 25.38
- PMN N/A
- 52 Week Low
- PIII $0.18
- PMN $0.87
- 52 Week High
- PIII $1.35
- PMN $2.61
- Technical
- Relative Strength Index (RSI)
- PIII 39.59
- PMN 47.06
- Support Level
- PIII $0.19
- PMN $0.89
- Resistance Level
- PIII $0.29
- PMN $1.02
- Average True Range (ATR)
- PIII 0.03
- PMN 0.08
- MACD
- PIII -0.00
- PMN -0.01
- Stochastic Oscillator
- PIII 4.30
- PMN 21.36
About PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About PMN ProMIS Neurosciences Inc. (ON)
ProMIS Neurosciences Inc is a clinical-stage biotechnology company focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine is based on the use of two complementary techniques. The company applies its thermodynamic, computational discovery platform-ProMIS and Collective Coordinates to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins.